APLAGON
Aplagon is committed to bringing unique, effective antithrombotic medicines with important safety advantages to patients with unmet needs.
APLAGON
Social Links:
Industry:
Pharmaceutical
Founded:
2009-01-01
Address:
Helsinki, Southern Finland, Finland
Country:
Finland
Website Url:
http://www.aplagon.com
Status:
Active
Contact:
+358 40 762 5159
Email Addresses:
[email protected]
Total Funding:
2.5 M EUR
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Euro Apple Mobile Web Clips Icon Google Font API Google Tag Manager WordPress Google Analytics 4 Fontello Kriesi.at
Similar Organizations
GMP Orphan
GMP Orphan is Identifying, developing and providing access to innovative treatments to patients with rare diseases.
Roche Diagnostics
Along with Roche Pharmaceuticals, Roche Diagnostics is an important part of the foundation that modern healthcare builds upon.
Investors List
European Innovation Council
European Innovation Council investment in Grant - Aplagon
European Innovation Council
European Innovation Council investment in Venture Round - Aplagon
Official Site Inspections
http://www.aplagon.com Semrush global rank: 6.08 M Semrush visits lastest month: 1.13 K
- Host name: web32.zoner.fi
- IP address: 5.44.244.42
- Location: Finland
- Latitude: 60.1717
- Longitude: 24.9349
- Timezone: Europe/Helsinki
More informations about "Aplagon"
Aplagon - Crunchbase Company Profile & Funding
Aplagon is committed to bringing unique, effective antithrombotic medicines with important safety advantages to patients with unmet needs.See details»
Aplagon - LinkedIn
Founded on pioneering research by Riitta Lassila and associates at the Wihuri Research Institute in Helsinki, Aplagon is a clinical-stage biopharmaceutical company dedicated to developing first-in ...See details»
Aplagon - fsg.vc
Aplagon is a biotech company pioneering the development of innovative, first-in-class therapies for thromboinflammatory diseases, which are driven by the interplay of thrombosis, โฆSee details»
Aplagon | thrombo-inflammatory diseases, APAC, Zoonop
Feb 3, 2025 Aplagon Oy is a clinical stage biopharmaceutical company established in 2009 and headquartered in Helsinki, Finland. It focuses on developing innovative therapeutics for โฆSee details»
Aplagon 2025 Company Profile: Valuation, Funding
Information on valuation, funding, cap tables, investors, and executives for Aplagon. Use the PitchBook Platform to explore the full profile.See details»
About Us โ Aplagon
Aplagon is a clinical-stage biopharmaceutical company developing first-in-class therapeutics for a wide range of thromboinflammatory diseases. Cardiovascular diseases carry significant morbidity and mortality.See details»
Aplagon - VentureRadar
"Aplagon is developing APACs, which are first-in-class, antithrombotic therapeutics for the prevention and treatment of blood vessel occlusions and management of ischemic reperfusion โฆSee details»
Aplagon Oy (Aplagon Oy) - ่ฏ็ฉ็ฎก็บฟ_ไธๅฉ_ไธดๅบ่ฏ้ช_ๆ่่ฅๆถ_ๆ โฆ
May 7, 2025 Aplagon Oy (Aplagon), a clinical stage biopharmaceutical company developing a first-in-class therapeutic (APAC, a heparin proteoglycan mimetic) for thrombo-inflammatory โฆSee details»
Focus on: Aplagon - pharmiweb.jobs
Jul 3, 2025 Aplagon is a clinical stage biopharmaceutical company developing a first-in-class therapeutic APAC for treating thrombo-inflammatory diseases. The companyโs first two lead โฆSee details»
Aplagon Company Profile - Office Locations, Competitors ... - Craft
Aplagon has 1 employees at their 1 location. See insights on Aplagon including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.See details»
Aplagon
Company Aplagon is a pharmaceutical discovery and development company. Aplagon is developing locally acting antithrombotic products (APACs), currently at late preclinical stage. โฆSee details»
Aplagon - app.biopharmiq.com
About: Aplagon is a clinical stage biopharmaceutical company developing first-in-class therapeutics for thromboinflammatory diseases. These include thrombotic, inflammatory and โฆSee details»
Aplagon - Funding, Financials, Valuation & Investors
Aplagon is committed to bringing unique, effective antithrombotic medicines with important safety advantages to patients with unmet needs.See details»
Investors โ Aplagon
Investors Aplagon is backed by a syndicate of leading Nordic investors including FSG Fund, Wihuri Foundation, Innovestor and Serlachius Foundation as well as EIC Fund.See details»
Pipeline โ Aplagon
The companyโs proprietary therapeutic APAC is a conjugate of two natural compounds: an albumin core covered by unfractionated heparin (UFH) chains. APAC can both prevent and โฆSee details»
Aplagon: Revenue, Worth, Valuation & Competitors 2025
Aplagon has an estimated revenue of -, and 7 employees. Alternatives of Aplagon are Riata Capital Group, Lighthouse Labs RVA and Altira Group.See details»
Finnish biotech startup Aplagon closes £7m to advance therapy for ...
Feb 3, 2025 Aplagon, a clinical stage biopharmaceutical company developing a first-in-class therapeutic for thrombo-inflammatory diseases, known as APAC, a heparin proteoglycan โฆSee details»
Science โ Aplagon
Mechanism of action Aplagonโs proprietary APAC is a dual AntiPlatelet and AntiCoagulant (APAC) with unique antithrombotic and anti-inflammatory properties. APAC (high negative charge) โฆSee details»
Aplagon Joins The TRACER Excellence Program to Perform In โฆ
Sep 8, 2022 For further information contact [email protected] or visit www.aplagon.com. About TRACER B.V. TRACER B.V. is a Clinical Research Organization (CRO) specializing in โฆSee details»